News & Updates
Filter by Specialty:
Pandemic babies have a 46 percent higher risk of atopic diseases
The incidence of atopic diseases in infants born in Hong Kong has increased by 46 percent during the COVID-19 pandemic, potentially linked to altered neonatal microbiome diversity resulting from vigorous disinfection. SIM03 and SIM05, symbiotic formulae developed with the aid of artificial intelligence (AI), are shown to improve eczema severity and quality of life (QoL) in children and adults, respectively, by modulating gut microbiota.
Pandemic babies have a 46 percent higher risk of atopic diseases
05 Feb 2025
Dupilumab trumps MTX, cyclosporine in paediatric AD
The use of dupilumab in children with moderate-to-severe atopic dermatitis (AD) results in greater improvements in AD severity, better adherence, and fewer treatment-emergent adverse events (TEAEs) than methotrexate (MTX) or cyclosporine, as shown by 2-year interim results from the PEDISTAD study.
Dupilumab trumps MTX, cyclosporine in paediatric AD
03 Feb 2025
Dupilumab-associated ocular surface disease less common in children, teens with AD
The incidence of ocular surface disease associated with dupilumab treatment for moderate-to-severe atopic dermatitis is lower in children and adolescents than that described in adults, suggests a retrospective review at a tertiary paediatric hospital in Singapore
Dupilumab-associated ocular surface disease less common in children, teens with AD
18 Jan 2025
Photosensitivity status in atopic dermatitis may change over time
Light sensitivity patterns vary in patients with atopic dermatitis (AD), reports a Scotland study, noting the significance of follow-up assessments because of potential shifts in disease spectrum over time.